TXNIP-IN-1 是硫氧还蛋白-硫氧还蛋白相互作用蛋白复合物抑制剂，来源于专利文献US20200085800A1（化合物 1）。它在 TXNIP-TRX 复合物相关代谢紊乱的糖尿病、心血管疾病或炎症疾病方面有研究的价值。

TXNIP-IN-1 is an inhibitor of the TXNIP-TRX complex and used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.

TXNIP-IN-1 bocks high glucose (HG induced) TXNIP-TRX complex formation.In monocytes, TXNIP-IN-1 (1.25-5 μM) reduces HG-induced expression of TNF . In THP1 cells,TXNIP-IN-1 (1.25-5 μM; 72 hours) inhibits TXNIP mRNA expression . TXNIP-IN-1 (0.3-10 μM; 72 hours) inhibits TXNIP mRNA expression in murine RAW macrophages. In MIN6 cells, TXNIP-IN-1 (5-20 μM; 72 hours) decreases TXNIP but not TNF-alpha mRNA levels . TXNIP-IN-1 (0.62-5 μM; 72 hours) affects TXNIP and TNF-alpha mRNA expression in human pancreas 1.1B4 beta cells. TXNIP-IN-1 (5 μM; 16-72 hours) inhibits c-TRX interaction in THP1 cells cultured in 25mM glucose. TXNIP-IN-1 targets TXNIP mRNA in human pancreatic islets.

1268955-50-5

C12H12N2O4

248.23

DMSO:50 mg/mL (201.43 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years